Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics Ltd.

December 04, 2014 08:00 ET

Ventripoint Appoints Dr. Alan Rabinowitz to Board of Directors

SEATTLE, WASHINGTON--(Marketwired - Dec. 4, 2014) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) is pleased to announce the appointment of Dr. Alan Rabinowitz to the Board of Directors.

Dr. Alan Rabinowitz is a cardiologist and President of the Medical Staff of St. Paul's Hospital, Vancouver, and Clinical Associate Professor in the Division of Cardiology at the University of British Columbia. He is the co-founder of PHEMI Health Systems and serves as Chief Medical Officer and a Director on the Board of that company.

"We are pleased to have someone with Dr. Rabinowitz's medical and business experience on the Board of Directors," stated Mr. Treuman Katz, Chairman of Ventripoint. "St. Paul's has had a VMS™ heart analysis system for two years and has recently had their clinical study accepted for publication in a major medical journal."

Dr. Rabinowitz received his medical degree from the University of Cape Town, South Africa, completed his internal medicine and cardiology training at the University of Toronto and undertook subsequent training in interventional cardiology at St. Paul's Hospital. In his previous capacity as Director of the Coronary Care Unit at St Paul's Hospital, Dr Rabinowitz recognized the critical importance of disruptive data solutions in transforming healthcare to enhance patient care, research and innovation, and improve sustainability of the healthcare ecosystem. This inspired the collaboration with data scientists and technology entrepreneurs out of which PHEMI Health Systems emerged.

"Every day large amounts of information, such as cardiac images, are collected and must be analyzed to provide actionable insights into patient care. The Ventripoint VMS does just this for the right heart," said Dr. Rabinowitz. "I look forward to assisting the Company to better understand and change the medical and business aspects of modern cardiac care in a hospital setting."

Dr. Rabinowitz also serves as a consultant to numerous medical institutions and organizations globally on medical innovation and system improvement, and has initiated and facilitated multiple international physician educational and practice exchanges.

As a new Director, Dr. Rabinowitz has been granted 225,000 Deferred Share Units (DSUs). Under the terms of the Company's DSU plan, holders of DSUs may redeem each DSU for one share of common stock upon the termination of their services to the Company, at no cost to the holder.

About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. The VMS is the first cost-effective and accurate tool for measuring right ventricle heart function, and is approved for clinical use for selected cardiac indications in Canada, Europe and the United States. The Company has a suite of applications for all major heart diseases and imaging modalities, including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information